KEYTRUDA® (pembrolizumab) in the treatment of advanced (unresectable or metastatic) melanoma

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma.

Click here to download KEYNOTE-006 clinical data presentation

PDF, 3.06 MB

A slide deck on KEYTRUDA in the treatment of patients with advanced (unresectable or metastatic) melanoma containing a clinical data presentation of KEYNOTE-006 as well as KEYNOTE-001 and KEYNOTE-002.

Please refer to the Summary of Product Characteristics for more information on adverse events associated with KEYTRUDA.

More information about KEYTRUDA® (pembrolizumab) in melanoma:

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website